MRTX849 acid

Target: This ligand targets KRAS G12C mutant protein in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for KRAS G12C mutant protein. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings KRAS G12C mutant protein into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated Kinase Degradation: MRTX849 acid can be leveraged as a kinase-binding ligand within PROTAC constructs to recruit an E3 ligase and drive selective degradation of its cognate target. This enables functional interrogation of kinase dependency by reducing target protein abundance rather than only inhibiting catalytic activity, often revealing degradation-specific phenotypes in cellular assays.

• Target Engagement and Turnover: Incorporating MRTX849 acid into PROTAC designs supports systematic evaluation of target engagement, ubiquitination, and proteasome-dependent turnover. By tuning linker length and E3 ligase recruiters, researchers can optimize degradation kinetics and extent, supporting mechanistic studies that distinguish reversible inhibition from sustained protein loss.

• Pathway Dissection via Degradation: PROTACs built with MRTX849 acid can be used to dissect downstream signaling pathways by comparing degradation versus inhibition outcomes. This approach helps identify whether phenotypes arise from complete protein depletion, partial destabilization, or transient occupancy, improving interpretation of kinase-driven cellular responses.

• Resistance Mechanism Studies: Using MRTX849 acid-based PROTACs enables investigation of resistance mechanisms that emerge under kinase-targeted pressure. Degradation-centric strategies can test whether resistant cells retain susceptibility to proteasomal elimination, and can map how alterations in target structure, E3 ligase engagement, or trafficking influence degradation efficiency.

MRTX849 acid is a KRAS G12C target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of MRTX849 acid is characterized by carboxylic acid or carboxylate handle; primary or secondary amine/basic nitrogen centers; halogenated aryl/heteroaryl ring system; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The acid handle supports amide coupling with amino-PEG, alkyl-diamine, piperazine, or aminoalkyl E3-ligase ligands. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.